21 October 2016 - - The biosurgery products market is set to reach USD 7.6bn by 2022, according to a new report from Dublin-based Research and Markets.

Prompt hemostasis, effective incision closure, tissue and vessel sealing, and post-operative adhesion prevention have been paramount concerns for surgeons for decades.

As medical technology advances, the surgeon's toolbox expands to include more effective products that actively cease bleeding, close external and internal ruptures in tissue, and provide physical barriers between tissues to prevent dangerous adhesions.

These biosurgery products have become indispensable keystones in any operating room environment.

Biosurgery products are experiencing steady growth across many countries. Emerging markets are expected to demonstrate the highest growth among the 15 market covered in the report, which are the US, Canada, Mexico, France, Germany, Italy, Spain, Russia, UK, Japan, China, India, South Korea, Australia, and Brazil.

The taxonomy of biosurgery included in this report covers hemostats, tissue sealants, tissue adhesives, and surgical adhesion barriers.

The global biosurgery market features two main players: J/J and Baxter.

Other prominent players include CryoLife, Sanofi, Pfizer, Integra LifeSciences, C.R. Bard, and B. Braun.
The entire market will be driven by aging populations, higher volumes of surgical procedures, and an increasing number of technological innovations.

Key Opinion Leaders emphasize the need for better mechanical properties, optimal biocompatibility, and need for less expensive products.